Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatmen... Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.17 | 5.86206896552 | 2.9 | 3.08 | 2.72 | 363691 | 2.82378567 | CS |
| 4 | 0.5 | 19.4552529183 | 2.57 | 3.08 | 2.526 | 433039 | 2.75375852 | CS |
| 12 | 0.12 | 4.06779661017 | 2.95 | 3.08 | 2.18 | 432865 | 2.56050712 | CS |
| 26 | -0.485 | -13.6427566807 | 3.555 | 4.53 | 2.18 | 708090 | 3.2781955 | CS |
| 52 | 1.23 | 66.847826087 | 1.84 | 4.53 | 1.7 | 682810 | 3.12933458 | CS |
| 156 | 2.37 | 338.571428571 | 0.7 | 4.64 | 0.2806 | 522601 | 2.33659138 | CS |
| 260 | -0.51 | -14.2458100559 | 3.58 | 4.64 | 0.2806 | 517872 | 2.03266425 | CS |
Paullee
4週前
rbl100
4週前
rbl100
4月前
MasterSalix
5月前
rbl100
5月前
rbl100
7月前
MasterSalix
7月前
rbl100
7月前
rbl100
8月前
Zadie420
8月前
rbl100
8月前
MasterSalix
9月前
rbl100
9月前
tw0122
9月前
rbl100
9月前
rbl100
9月前
rbl100
9月前
MasterSalix
9月前
rbl100
9月前
rbl100
9月前
MasterSalix
9月前
rbl100
9月前
rbl100
9月前
rbl100
9月前
rbl100
10月前
rbl100
10月前
rbl100
10月前
rbl100
10月前
rbl100
10月前
rbl100
10月前
rbl100
1年前
rbl100
1年前
rbl100
1年前
Paullee
1年前
rbl100
1年前
nbm16yankees
1年前
Paullee
1年前
nbm16yankees
1年前
rbl100
1年前
rbl100
1年前
rbl100
1年前
rbl100
1年前
rbl100
1年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。